Craig Mello named winner of The Dr. Paul Janssen Award for Biomedical Research

September 12, 2006

Beerse, Belgium - September 12, 2006 - Johnson & Johnson today announced that Craig C. Mello, Ph. D., a professor of Molecular Medicine at the University of Massachusetts Medical School, Worcester, MA, and an investigator at the Howard Hughes Medical Institute, has been named the inaugural recipient of The Dr. Paul Janssen Award for Biomedical Research. Dr. Mello was selected for his role in the discovery of RNA interference (RNAi) and the elucidation of its biological functions. The Award will be presented to Dr. Mello today at The Dr. Paul Janssen Biomedical Research Scientific Symposium and Award Program in Beerse, Belgium, which also commemorates the 80th anniversary of Dr. Janssen's birth. The Dr. Paul Janssen Award for Biomedical Research was established by Johnson & Johnson to honor Dr. Paul Janssen. The Award recipients are chosen by a preeminent and independent selection committee composed of world-leading scientists and clinicians. Intending to acknowledge a scientist whose work has the potential to make a significant, transformational contribution toward the improvement of human health, the Award includes a $100,000 prize and will be given every two years. Dr. Janssen, who was known to his colleagues as Dr. Paul, was one of the 20th century's most gifted and passionate scientists. At the time of his death in 2003, Dr. Paul, who was the founder of Janssen Pharmaceutica, had contributed to the discovery and development of more than 80 medicines that have helped save millions of lives.

"I am very grateful to receive this Award, which aims to extend the legacy of Dr. Paul Janssen, one of the greatest scientific innovators of our time," said Dr. Mello. "I am also very thankful to the Selection Committee for giving me this Award and to be considered alongside so many great scientists."

RNA interference is a biological process where double-stranded RNA inhibits gene expression in a highly specific fashion. Since its discovery in 1998, RNA interference has emerged as a powerful "gene-silencing" technique used in laboratories around the world to determine which genes are important in various diseases and conditions. RNAi also has promise as the basis of gene-silencing therapies. The new field of RNAi-based genomics is a fundamental paradigm shift for biomedical research and has the potential to start a revolution in the development of modern therapeutics.

"Johnson & Johnson is very pleased to award The Dr. Paul Janssen Award for Biomedical Research to Dr. Mello," said William C. Weldon, Chairman, Board of Directors, and Chief Executive Officer of Johnson & Johnson. "His work and research have the potential to help millions of people, and this epitomizes the passion, leadership and innovation that defined Dr. Janssen."

Among Mello's other honors, he has received the 2006 Paul Ehrlich and Ludwig Darmstaedter Prize; the Dr. Lewis S. Rosentiel Award for Distinguished Work in Basic Medical Science; the Gairdner Foundation International Award; the National Academy of Sciences Award in Molecular Biology; the Wiley Prize in Biomedical Sciences; the Warren Triennial Prize, Massachusetts General Hospital; and the Massry Prize.

"Now more than ever, scientific innovation comes at a premium," says Sir Richard Sykes, a member of the Award's international Selection Committee. "Discoveries such as those by Dr. Mello have the potential to open a treasure chest of untold medical innovations that can ultimately help patients on a worldwide basis."

"Dr. Mello is a very deserving recipient of this auspicious award," said Dr. Snyder. "The Committee was faced with a very difficult challenge to select the inaugural recipient for this award. We feel that Dr.Mello's innovative work opens up new pathways to understanding basic biology and will have a true impact on human health."
About The Selection Committee
The Award's independent, international Selection Committee included: For more information about the Award, please go to

About Johnson & Johnson
Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 230 Johnson & Johnson operating companies employ approximately 116,000 men and women in 57 countries and sell products throughout the world.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Related Biomedical Research Articles from Brightsurf:

General data protection regulation hinders global biomedical research
The European Union (EU) General Data Protection Regulation (GDPR) was designed to give EU citizens greater protection and control of their personal data, particularly when transferred to entities outside the EU.

Novel educational program puts a human face on biomedical research
The goal of translational research is to speed research breakthroughs into clinical practice.

Biomedical research may miss key information by ignoring genetic ancestry
A new study of Black residents of four distinct US cities reveals variations in genetic ancestry and social status that underscore the inadequacy of using skin color as a proxy for race in research.

Advances in cryo-EM materials may aid cancer and biomedical research
Cryogenic-Electron Microscopy (cryo-EM) has been a game changer in the field of medical research, but the substrate, used to freeze and view samples under a microscope, has not advanced much in decades.

World-first program uncovers errors in biomedical research results
Just like the wrong ingredients can spoil a cake, so too can the wrong ingredients spoil the results in biomedical research.

Scientists poised to study reproducibility of Brazilian biomedical research
A project to assess the reproducibility of biomedical research in Brazil has been described today in the open-access journal eLife.

Transparency and reproducibility of biomedical research is improving
New research publishing Nov. 20 in the open-access journal PLOS Biology from Joshua Wallach, Kevin Boyack, and John Ioannidis suggests that progress has been made in key areas of research transparency and reproducibility.

As private funding of biomedical research soars, new risks arise
Academic medical centers (AMCs) in the US are navigating an increasing shift in research funding from historic public funding (e.g., NIH) to private sources such as pharma and biotech companies, foundations, and charities, raising a host of new issues related to collaborative research models, intellectual property rights, and scientific and ethical oversight.

BGRF scientists co-publish research paper on blockchain & AI for biomedical applications
Biogerontology Research Foundation Chief Science Officer (CSO) co-authored the landmark paper in the journal Oncotarget on the convergence of blockchain and AI to decentralize and galvanize healthcare and biomedical research.

Promising new drug for Hep B tested at Texas Biomedical Research Institute
Research at the Southwest National Primate Research Center (SNPRC) on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.

Read More: Biomedical Research News and Biomedical Research Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to